Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Up 14.9 %

Shares of NASDAQ:BCLI opened at $1.12 on Friday. The company’s fifty day moving average is $1.30 and its two-hundred day moving average is $1.66. Brainstorm Cell Therapeutics has a 12-month low of $0.72 and a 12-month high of $10.05. The company has a market cap of $7.30 million, a P/E ratio of -0.23 and a beta of 0.60.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.